Lung cancer in the Indian subcontinent
Authors:
Open Access
- 1 July 2016
- journal article
- review article
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 05 (03) , 095-103
Abstract
Smoking tobacco, both cigarettes and beedis, is the principal risk factor for causation of lung cancer in Indian men; however, among Indian women, the association with smoking is not strong, suggesting that there could be other risk factors besides smoking. Despite numerous advances in recent years in terms of diagnostic methods, molecular changes, and therapeutic interventions, the outcomes of the lung cancer patients remain poor; hence, a better understanding of the risk factors may impact the preventive measures to be implemented at the community level. There is a lack of comprehensive data on lung cancer in India. In this review, we attempt to collate the available data on lung cancer from India.Keywords
This publication has 46 references indexed in Scilit:
- Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian EthnicityPLOS ONE, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted TherapyPLOS ONE, 2013
- A year of anaplastic large cell kinase testing for lung carcinoma: Pathological and technical perspectivesIndian Journal of Cancer, 2013
- Personalized medicine: Lung Cancer leads the wayIndian Journal of Cancer, 2013
- Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experienceLung India, 2013
- First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patientsIndian Journal of Medical and Paediatric Oncology, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005